Lyell Immunopharma, Inc. — Director's Dealing 2026

Jan 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-12-24

Reporting Person: Bulis Veronica Sanchez (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-24	Common Stock	S	1136	$38.67	Disposed	8077	Direct
2025-12-30	Common Stock	S	936	$32.32	Disposed	7141	Direct

Footnotes

F1: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $38.6643 to $38.6751 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.